Erector Spinae Versus Paravertebral in Pediatric PCNL

Ultrasound-guided Erector Spinae Plane Block Versus Ultrasound-guided Thoracic Paravertebral Block in Pediatric Patients Undergoing Percutaneous Nephrolithotomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05589649

Enrollment

Registered

2022-10-21

Start date

2022-10-26

Completion date

2023-12-27

Last updated

2024-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithotomy, Percutaneous, Renal Stone

Keywords

paravertebral block, Erector spinae plane block, Percutaneous nephrolithotomy, pediatric

Brief summary

To compare the efficacy of ultrasound-guided erector spinae plane block versus ultrasound-guided paravertebral block in pediatric patients undergoing percutaneous nephrolithotomy

Detailed description

Percutaneous Nephrolithotomy (PCNL) is a commonly performed surgical procedure for complex upper renal tract calculi. Although the skin incision for PCNL appears small, the intensity of intraoperative and postoperative pain is significant owing to soft tissue injury. Erector spinae plane (ESP) block is an interfascial block that was first described by Forero et al. in 2016. It can be performed by injecting the local anesthetic in the deep interfascial plane of the erector spinae muscle to provide both visceral and somatic analgesia with a sensory level from T2-4 to L1-2. . Paravertebral block is the technique of injecting local anesthetics in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is used increasingly for intra-operative and post-operative.

Interventions

PROCEDUREErector spinae plane block

Ultrasound-guided erector spinae plane block

PROCEDUREParavertebral block

Ultrasound-guided paravertebral block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Patients undergoing percutaneous nephrolithotomy

Exclusion criteria

* Coagulation disorders * Infection at the site of injection * Allergy to the local anesthetics used * Spinal cord abnormalities or neurological deficits

Design outcomes

Primary

Measure	Time frame
Total consumption of nalbuphine	The first 24 hours postoperatively
Time to first rescue analgesia	The first 24 hours postoperatively

Secondary

Measure	Time frame
The concentration of sevoflurane in percent	Through the surgery, an average of 2 hours
Systolic, diastolic, and mean blood pressure during surgery in mmHg	Through the surgery, an average of 2 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026